The convergence of entities in this cluster reflects a maturing phase in incretin-based pharmacotherapy, moving beyond simple efficacy demonstrations toward nuanced, comparative, and mechanistic understanding. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) and the dual/multi-agonist successors (tirzepatide, and emerging GLP-1R-GIPR-PPARα/γ/δ quintuple agonism) continue to demonstrate robust effects on weight loss, HbA1c reduction, and BMI reduction across adult and pediatric diabetes/obesity populations. However, the field is now characterized by head-to-head differentiation: tirzepatide consistently shows superior metabolic outcomes and composite outcome rates versus semaglutide, while network meta-analyses reveal a critical body-composition trade-off—greater fat mass reduction with dual/triple agonists comes at the cost of larger absolute lean mass losses (semaglutide alone showing losses up to 5.44 kg), a finding that is reshaping clinical counseling and drug selection, particularly for patients concerned about functional outcomes and sarcopenia risk. SGLT2 inhibitors emerge as comparators with more modest fat loss but minimal lean mass impact, positioning them as an alternative in select cardiometabolic populations.
A second major trajectory is the extension of these agents into MASH/MASLD, where semaglutide shows meaningful MASH resolution (OR 3.48) and improvement in imaging/biochemical markers, but fails to achieve statistically significant histological fibrosis improvement in pooled analyses—an effect described as stage- and time-dependent, with current trial endpoints criticized as too short to capture true anti-fibrotic efficacy. This is reinforced by real-world, multicenter, propensity-matched comparative effectiveness studies pitting semaglutide against SGLT2 inhibitors in MASLD/MASH populations, signaling a shift from RCT-only evidence toward pragmatic, EHR-derived real-world data (e.g., the 45,093-patient real-world comparison of semaglutide, tirzepatide, and sleeve gastrectomy) to guide treatment sequencing, including comparisons with bariatric surgery (higher composite outcome with sleeve gastrectomy but at the cost of increased ED utilization).
Finally, the cluster highlights an evolving safety and maintenance paradigm: pharmacist-focused narrative reviews synthesize safety monitoring needs around semaglutide (including signals like suicidal ideation and telogen effluvium/hair loss linked to rapid weight loss), while the ATTAIN-MAINTAIN trial introduces orforglipron as an oral maintenance strategy to sustain weight loss after weight plateau following injectable GLP-1RA therapy (tirzepatide or semaglutide). Collectively, these threads point to a field pivoting from establishing incretin efficacy toward optimizing long-term safety, body composition quality, fibrosis-specific endpoints, oral maintenance options, and comparative positioning against both older antidiabetic classes and surgical interventions.